Orchid Pharma Share Price
(ORCHPHARMA)
₹874.55▲4.99%
as on 04:01PM, 20 Feb 2025
🔔 Regulatory Alert
Orchid Pharma's Alathur facility successfully completed a USFDA inspection with seven minor observations, maintaining its status as India's only USFDA-approved site for sterile cephalosporins.
Orchid Pharma Performance
Day's Low
₹824.25Day's Price Range₹874.5552 Week's Low
52 Week's High
₹800.8552-Week Price Range₹1,997.4
| Returns % | |
| 1 Month Return | -49.52 % |
| 3 Month Return | -43.63 % |
| 1 Year Return | -24.59 % |
| Market Stats | |
| Previous Close | ₹832.95 |
| Open | ₹837.00 |
| Volume | 78.83K |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹4,224.65Cr |
Orchid Pharma Key Statistics
P/E Ratio
37.74
PEG Ratio
-7.95
Market Cap
₹4,224.65 Cr
P/B Ratio
4.61
EPS
18.74
Dividend Yield
0Sector
Pharmaceuticals
ROE
3.15
Orchid Pharma Mutual Fund Holdings
Orchid Pharma Analyst Rating
based on 3 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 3 analysts offering long term price targets for Orchid Pharma. An average target of ₹1498.67
Source: S&P Global Market Intelligence
Orchid Pharma Share analysis
Orchid Pharma price forecast by 3 analysts
Upside of79.92%
High
₹1641
Target
₹1498.67
Low
₹1285
Orchid Pharma target price ₹1498.67, a slight upside of 79.92% compared to current price of ₹874.55. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Orchid Pharma revenue growth forecast
Expected growth rate Q1, FY2027:169.10%
Forecast
Actual
Including amortisation and stock based compensations
Orchid Pharma EPS growth forecast
EPS estimate Q1, FY2027:370.56%
Forecast
Actual
Source: S&P Global Market Intelligence
What's happening today
Today's Timeline - Invalid Date
11:30 AM
-Orchid Pharma hits 5% upper circuit after USFDA inspection at Tamil Nadu facility with seven minor observations.
Key events for Orchid Pharma Ltd
Orchid Pharma's FDA Inspection Yields Minor Observations - 19 Feb, 2025
Orchid Pharma's Alathur facility underwent a surprise FDA inspection, resulting in seven minor observations. The facility maintains its USFDA approval for sterile cephalosporins, ensuring compliance with regulatory standards.Orchid Pharma Reports Decline in Q4 Financials - 17 Feb, 2025
Orchid Pharma's standalone net sales for December 2024 fell 1.47% year-on-year to Rs 217.34 crore. Net profit decreased by 21.74% to Rs 23.91 crore, while EBITDA dropped 16.24%. The EPS also declined to Rs 4.71. The stock has seen significant losses, with -32.07% returns over the last 6 months and -15.66% over the last year.Orchid Pharma Faces Revenue Challenges but Long-Term Outlook Remains Positive - 14 Feb, 2025
Orchid Pharma missed Q3 revenue and profit estimates, with a 2% YoY revenue decline due to pricing pressures. Despite cutting FY26E and FY27E EPS by ~15%, the long-term outlook remains positive, supported by NCE royalties and new opportunities. Nuvama maintains a 'BUY' rating with a revised target of Rs 1,570.Orchid Pharma Shares Plummet After Q3 Results - 13 Feb, 2025
Orchid Pharma's shares fell over 14% following a 25.63% decline in net profit to ₹22.45 crore for Q3. Revenue also dropped 1.37% year-on-year, leading to significant volatility in stock performance.
Insights on Orchid Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 1.94% to 2.53% in Dec 2024 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ORCHPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 16.78% to 17.46% in Dec 2024 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 59.9% return, outperforming this stock by 84.4%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 69.84% of holdings in Dec 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 7 days, ORCHPHARMA stock has moved down by -20.5%
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 4 quarters, 32.96 Cr → 20.78 Cr (in ₹), with an average decrease of 14.0% per quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 251.98 Cr → 225.83 Cr (in ₹), with an average decrease of 5.3% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 9.93% to 8.64% in Dec 2024 quarter
Orchid Pharma Financials
Index Inclusions
Orchid Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 69.84% | 0.00 | |
| Foreign Institutions | 2.53% | 30.66 | |
| Mutual Funds | 17.46% | 4.02 | |
| Retail Investors | 8.64% | ||
| Others | 1.54% | 1.74 |
Orchid Pharma Key Indicators
Orchid Pharma Valuation
Orchid Pharma in the last 5 years
Lowest (-871.56x)
April 8, 2022
Today (37.74x)
February 19, 2025
Industry (51.87x)
February 19, 2025
Highest (105.04x)
September 14, 2022
Orchid Pharma Earnings and Dividends
Orchid Pharma Ltd Earnings Results
Orchid Pharma Ltd’s net profit fell -29.39% since last year same period to ₹20.78Cr in the Q3 2024-2025. On a quarterly growth basis, Orchid Pharma Ltd has generated -23.72% fall in its net profits since last 3-months.
Read More about Earnings Results
Orchid Pharma Technicals Summary
Bearish
Neutral
Bullish
Orchid Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.
Orchid Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,224.65 Cr | 905.5% | 0.55 | ₹95 Cr | ₹819 Cr | |
| NA | ₹102.38 Cr | 43.14% | 0.73 | NA | NA | |
| HOLD | ₹14,561.63 Cr | 4.54% | 0.54 | ₹1,388 Cr | ₹3,998 Cr | |
| BUY | ₹7,790.22 Cr | -7.57% | 0.00 | ₹97 Cr | ₹4,178 Cr | |
| NA | ₹368.31 Cr | 191.73% | 0.54 | ₹23 Cr | ₹164 Cr |
About Orchid Pharma
Share Price: ₹874.55 per share as on 20 Feb, 2025 04:01 PM
Market Capitalisation: ₹4,224.65Cr as of today
Revenue: ₹217.34Cr as on December 2024 (Q4 24)
Net Profit: ₹22.45Cr as on December 2024 (Q4 24)
Listing date: 12 May, 1995
Chairperson Name: Ram Gopal Agarwal
| Organisation | Orchid Pharma |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Orchid Pharma Ltd
What is Orchid Pharma Ltd price today?
Orchid Pharma Ltd share price today stands at ₹874.55, Open: ₹837, Previous Close: ₹832.95, High: ₹874.55, Low: ₹824.25, 52 Week High: ₹1997.4, 52 Week Low: ₹800.85.
How to Buy Orchid Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Orchid Pharma Ltd shares
Is Orchid Pharma Ltd listed on NSE?
Orchid Pharma Ltd is listed on NSE
Is Orchid Pharma Ltd listed on BSE?
Orchid Pharma Ltd is listed on BSE
What are today's High and Low prices of Orchid Pharma Ltd?
- Today's highest price of Orchid Pharma Ltd is ₹874.55.
- Today's lowest price of Orchid Pharma Ltd is ₹824.25.
What are today's traded volumes of Orchid Pharma Ltd?
Today's traded volume of Orchid Pharma Ltd(ORCHPHARMA) is 78.83K.
What is today's market capitalisation of Orchid Pharma Ltd?
Today's market capitalisation of Orchid Pharma Ltd(ORCHPHARMA) is ₹4224.65Cr.
What is the 52 Week High and Low Range of Orchid Pharma Ltd?
How much percentage Orchid Pharma Ltd is down from its 52 Week High?
Orchid Pharma Ltd (ORCHPHARMA) share price is ₹874.55. It is down -56.22% from its 52 Week High price of ₹1997.4
How much percentage Orchid Pharma Ltd is up from its 52 Week low?
Orchid Pharma Ltd (ORCHPHARMA) share price is ₹874.55. It is up 9.20% from its 52 Week Low price of ₹800.85
What are the historical returns of Orchid Pharma Ltd?
What is the PE ratio of Orchid Pharma Ltd today?
PE Ratio of Orchid Pharma Ltd is 37.74
PE ratio = Orchid Pharma Ltd Market price per share / Orchid Pharma Ltd Earnings per share